Division of Surgical Oncology, Department of Surgery, NYU Langone Health, New York University Grossman Long Island School of Medicine, Mineola, NY, USA.
Division of Surgical Oncology, Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, James Cancer Hospital, Columbus, OH, USA.
Ann Surg Oncol. 2024 Jan;31(1):75-80. doi: 10.1245/s10434-023-14420-4. Epub 2023 Oct 16.
Until recently, there have been only modest therapeutic advances in the treatment of hepatobiliary malignancies. However, the introduction of immune checkpoint inhibitors in combination with targeted therapy or chemotherapy has changed the therapeutic landscape of hepatocellular carcinoma and biliary tract cancers. As such, revisions have been made to guidelines reflecting therapeutic advances for patients who can be considered for surgical options including resection and liver transplantation. This article highlights recently published studies that have impacted both the oncological and surgical approach to the treatment of patients with hepatobiliary malignancies.
直到最近，肝胆恶性肿瘤的治疗才取得了适度的进展。然而，免疫检查点抑制剂与靶向治疗或化疗联合应用改变了肝细胞癌和胆管癌的治疗格局。因此，对于可以考虑手术治疗（包括切除和肝移植）的患者，指南进行了修订以反映治疗进展。本文重点介绍了最近发表的研究，这些研究对肝胆恶性肿瘤患者的肿瘤学和手术治疗方法都产生了影响。
